trending Market Intelligence /marketintelligence/en/news-insights/trending/kr5vbd_o674xjm0tjii-ug2 content esgSubNav
In This List

Medicines Co. to reduce board size

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Medicines Co. to reduce board size

Parsippany, N.J.-based Medicines Co. is reducing the size of its board to seven members from 12 members and nominating new directors for the 2018 annual meeting of shareholders.

The company said the changes to the board are a result of the changes in its business and the narrowing of its operational focus onto cholesterol drug inclisiran.

Alexander Denner, Fredric Eshelman, Geno Germano, John Kelly, Clive Meanwell, Paris Panayiotopoulos and Sarah Schlesinger are among the slate of nominees up for election at the annual meeting.

Denner has been the chief investment officer and founding partner at Sarissa Capital Management LP since 2012. Sarissa Capital, which is an active investor in the healthcare sector, owns 2.66% of Medicines Co., according to S&P Global Market Intelligence data.